Main Conference - Day 1 Keynote Sessions (May 15)
Main Conference - Day 1 Keynote Sessions (May 15)
- Andreas Wagner - Head Liposome Technology, Polymun Scientific GmbH
- Mahesh Karwa, PhD - Director, Process & Analytical Development, MilliporeSigma
- Aaron Cowley, PhD - Chief Scientific Officer, ReciBioPharm
- Muthiah (Mano) Manoharan, PhD - Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals
- Frank Bennett, PhD - Executive Vice President and Chief Scientific Officer, Ionis Pharmaceuticals
- George Church, PhD - Professor of Genetics, Harvard Medical School
- Kyle Schneider, PhD - R&D Director, Vestaron
- Joe Lewcock, PhD - Chief Scientific Officer, Denali Therapeutics
Aldevron’s significantly expanded mRNA capabilities includes enhancements to drug product and drug substance manufacturing, as well as advanced analytical testing capabilities. At this luncheon, learn more about those advancements, and how Aldevron continues to expand its sequence-to-vial mRNA ecosystem.
- Tao Lu - Senior Director, RNA Product Management, Aldevron
- Marco Minuth, PhD - Director Oligo R&D II, Bachem
- Sirat Sikka - Senior Scientist, Applications & Innovation, Thermo Fisher Scientific
- Chunping Xu, Ph.D - Sebior Director of Chemistry R&D, TriLink BioTechnologies
- Ingo Röhl, PhD - Managing Director Analytics, Axolabs
- Songjun Xiao, PhD - process development senior scientist, LGC Axolabs
- John Batal - Director of Engineering, Nitto Avecia
- Mimoun Ayoub, PhD - Senior VP, Global Head of Sales and Key Account Management, CordenPharma International
- Meg Brousseau, Ph.D. - Executive Director, Cardiovascular & Metabolic Diseases, Novartis
- Jacob Hyllested-Winge, M.D. - Project Vice President, Boston Global Development, Novo Nordisk
The discovery of the incretin system and the therapeutic benefits of glucagon-like peptide 1 (GLP-1) has prompted a wave of innovation, resulting in new classes of highly effective therapies for type 2 diabetes. Leveraging these therapies for their weight regulation effects has produced a fresh wave of innovation and the advent of novel, highly effective therapies for weight management. We will review emerging gut peptide-derived therapeutics for glucose and weight management, their mechanisms of action, and some unknowns and controversies.
- Kieren Mather, MD - Associate VP-Medical-Incretins and Diabetes Breakthroughs, Early Clinical Research, Eli Lilly and Company
This panel will explore the anticipated technical and clinical advancements in mRNA medicine over the next 3-5 years that will show the utility of the field in addressing key unmet medical needs in oncology, infectious disease, cardiovascular disease, automimmune, and rare diseases. This will include discussions of saRNA, circular RNA, and the critical role mRNA and non-viral delivery are playing in various gene and base editing modalities.
- Andrew Geall, PhD - Co-founder and Chief Development Officer, Replicate Bioscience
- Roberta Duncan - Chief Strategy Officer, Arcturus Therapeutics
- Jeffery Coller, PhD - Bloomberg Distinguished Professor of RNA Biology and Therapeutics, Johns Hopkins University
- Ariel Kantor, PhD - SVP, Head of Business and Corporate Development, ReCode Therapeutics